Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker Studies
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Although it has long been appreciated that ovarian carcinoma subtypes (serous, clear cell, endometrioid, and mucinous) are associated with different natural histories, most ovarian carcinoma biomarker studies and current treatment protocols for women with this disease are not subtype specific. With the emergence of high-throughput molecular techniques, distinct pathogenetic pathways have been identified in these subtypes. We examined variation in biomarker expression rates between subtypes, and how this influences correlations between biomarker expression and stage at diagnosis or prognosis. METHODS AND FINDINGS: In this retrospective study we assessed the protein expression of 21 candidate tissue-based biomarkers (CA125, CRABP-II, EpCam, ER, F-Spondin, HE4, IGF2, K-Cadherin, Ki-67, KISS1, Matriptase, Mesothelin, MIF, MMP7, p21, p53, PAX8, PR, SLPI, TROP2, WT1) in a population-based cohort of 500 ovarian carcinomas that was collected over the period from 1984 to 2000. The expression of 20 of the 21 biomarkers differs significantly between subtypes, but does not vary across stage within each subtype. Survival analyses show that nine of the 21 biomarkers are prognostic indicators in the entire cohort but when analyzed by subtype only three remain prognostic indicators in the high-grade serous and none in the clear cell subtype. For example, tumor proliferation, as assessed by Ki-67 staining, varies markedly between different subtypes and is an unfavourable prognostic marker in the entire cohort (risk ratio [RR] 1.7, 95% confidence interval [CI] 1.2%-2.4%) but is not of prognostic significance within any subtype. Prognostic associations can even show an inverse correlation within the entire cohort, when compared to a specific subtype. For example, WT1 is more frequently expressed in high-grade serous carcinomas, an aggressive subtype, and is an unfavourable prognostic marker within the entire cohort of ovarian carcinomas (RR 1.7, 95% CI 1.2%-2.3%), but is a favourable prognostic marker within the high-grade serous subtype (RR 0.5, 95% CI 0.3%-0.8%). CONCLUSIONS: The association of biomarker expression with survival varies substantially between subtypes, and can easily be overlooked in whole cohort analyses. To avoid this effect, each subtype within a cohort should be analyzed discretely. Ovarian carcinoma subtypes are different diseases, and these differences should be reflected in clinical research study design and ultimately in the management of ovarian carcinoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
World Health Organization Classification of Tumours
Fletcher, C., van den Berg, A., & Molenaar, I. (2002) · Cited by 7,079
Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK)
McShane, L. M., Altman, D. G., Sauerbrei, W., Taube, S. E., Gion, M., & Clark, G. M. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji237 · Cited by 2,162
Shih, I.-M., & Kurman, R. J. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63708-x · Cited by 1,206
du Bois, A. (2003) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/djg036 · Cited by 1,113 · cited 1×
“The dismal response rate of clear cell carcinomas (15%) contrasts sharply with that of high-grade serous (80%), resulting in a lower 5-y survival for clear cell compared with high-grade serous carcinoma in patients with advanced stage tumors (20% versus 30%) [7,8].”
BackgroundWright, G., Tan, B., Rosenwald, A., Hurt, E. H., Wiestner, A., & Staudt, L. M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1732008100 · Cited by 1,040 · cited 1×
“, breast carcinoma and lymphoma [24,25]), and this subtype specific approach to treatment has implications for the design of clinical trials for women with ovarian carcinomas.”
BackgroundGrading Ovarian Serous Carcinoma Using a Two-Tier System
Malpica, A., Deavers, M. T., Lu, K., Bodurka, D. C., Atkinson, E. N., Gershenson, D. M., & Silva, E. G. (2004) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200404000-00009 · Cited by 670 · cited 1×
“The serous subtype was further subdivided into low- and high-grade [11].”
BackgroundLu, K. H., Patterson, A. P., Wang, L., Marquez, R. T., Atkinson, E. N., Baggerly, K. A., Ramoth, L. R., Rosen, D. G., Liu, J., Hellstrom, I., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0409 · Cited by 440 · cited 1×
“For example, CA125 is expressed in most high-grade serous carcinoma, but only in 60% of mucinous and clear cell subtypes, a finding that is consistent with previous studies [26].”
ResultSchwartz, D. R., Kardia, S. L. R., Shedden, K., Kuick, R. D., Michailidis, G. C., Taylor, J. M. G., Misek, D. E., WU, R. T., Zhai, Y., Darrah, D. M., et al. (2002) · PubMed · Cited by 430
Singer, G., Stöhr, R., Cope, L., Dehari, R., Hartmann, A., Cao, D.-F., Wang, T.-L., Kurman, R. J., & Shih, I.-M. (2005) · American Journal of Surgical Pathology · doi:10.1097/01.pas.0000146025.91953.8d · Cited by 408 · cited 1×
“The goal of our marker selection was to use proteins that are consistently expressed in ovarian carcinomas and have been reported as prognosticators (p53, p21, Ki-67, PR, WT1) [”
MethodZorn, K. K., Bonome, T., Gangi, L., Chandramouli, G. V. R., Awtrey, C. S., Gardner, G. J., Barrett, J. C., Boyd, J., & Birrer, M. J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0508 · Cited by 376 · cited 1×
“Each of theses subtypes is associated with different genetic risk factors and molecular events during oncogenesis [1,2], and characterized by distinct mRNA expression profiles [3,4].”
Background
Research works printed but not linked: 2
- Swenerton KD 2008 Ovarian carcinoma treatment guidelines of the British Columbia Cancer Agency Available: http://www.bccancer.bc.ca/PPI/TypesofCancer/Ovary/default.htm. Accessed 1 April 2000
- Turbin DA Leung S 2008 GPEC plugin for Image J an image analyzing software Available: http://www.gpec.ubc.ca/index.php?content=software/imagej_plugin/index.php. Accessed 20 April 2008
Cited by
Items 701–800 of 895
Kohn, E. C. (2014) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2014.34.139 · Cited by 2
Kommoss, S., Kommoss, F. K. F., Diebold, J., Lax, S., Schmidt, D., Staebler, A., du Bois, A., & Pfisterer, J. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.416 · Cited by 2
“…and more desirable considering our recent findings of clinically relevant diagnostic discrepancies in a clinical trial patient cohort and in the light of the upcoming era of modern histotype-specific ovarian carcinoma treatment (Kobel et al, 2008; McCluggage, 2011; Prat, 2012; Kommoss et al, 2013).”
Advancing the Care of Pancreatic Cancer Patients: Moving Beyond Just Tumour Tissue
Kalloger, S. E., Karasinska, J. M., Warren, C., Renouf, D. J., & Schaeffer, D. F. (2021) · Biomarker Insights · doi:10.1177/11772719211049852 · Cited by 2
Self-citationMolecular Genetic Markers in Female Reproductive Cancers
Wang, T., Davidson, B., Buckhaults, P., Huang, C., & Pohl, G. (2010) · Journal of Oncology · doi:10.1155/2010/307460 · Cited by 2
Gavrielides, M. A., Ronnett, B. M., VANG, R. S., & Seidman, J. D. (2015) · Proceedings of SPIE, the International Society for Optical Engineering/Proceedings of SPIE · doi:10.1117/12.2082264 · Cited by 2
Morphological and Molecular Pathogenesis of Epithelial Ovarian Tumors
Tashiro, H., Imamura, Y., Motohara, T., Sakaguchi, I., & Katabuchi, H. (2017) · Comprehensive gynecology and obstetrics · doi:10.1007/978-981-10-4160-0_3 · Cited by 2
Yuan, S., Qiao, T., Qiang, J., & Cai, S. (2019) · Oncology Reports · doi:10.3892/or.2019.7124 · Cited by 2
“Taxanes-platinum combination have become the first-line chemotherapeutic regimen used against advanced epithelial ovarian cancer (EOC), which accounts for 85-90% of all ovarian malignancies (2).”
BackgroundAn, Y., & Duan, H. (2022) · Disease Markers · doi:10.1155/2022/7900785 · Cited by 2
Patankar, N. A. (2010) · cIRcle (University of British Columbia) · doi:10.14288/1.0071510 · Cited by 2
Stamelos, V. A. (2014) · Keele Research Repository (Keele University) · Cited by 2
Khan, G. N. (2016) · University of Bedfordshire Repository (University of Bedfordshire) · Cited by 2
The clinicopathologic significance of psammoma bodies in cytology specimens: A series of 78 cases
Braun, A., Hassan, D., Findley, J., Cheng, L. L., & Yan, L. (2024) · Diagnostic Cytopathology · doi:10.1002/dc.25383 · Cited by 1
“24 According to a study by Köbel et al., 25 psammoma bodies were observed in 92% of high-grade serous carcinomas examined.”
World Ovarian Cancer Day: unravelling the molecular anatomy of a silent killer
Kanneganti, A., Low, J. J. H., Huang, R. Y., & Choolani, M. (2026) · Singapore Medical Journal · doi:10.4103/singaporemedj.smj-2026-255 · Cited by 1
“As an immunologically ‘cold’ cancer with few infiltrating T cells, [3] poor vascularisation [4] and biological heterogeneity, [5,6] there is no biomarker that is consistently and adequately shed into the circulation to facilitate early detection.”
Jain, A., Saxena, R., Omhare, A., Fatima, A., Saxena, R., Hashmi, S. Z. A., Singh, K., & Paul, R. (2026) · Cureus · doi:10.7759/cureus.114047 · Cited by 1
DNA circuits for biomarker detection: from signal amplification to molecular logic
He, Z., Yi, Y., Mi, M., Xiong, T., Wu, X., Zou, T., Zhang, J., & Liang, W. (2026) · Analytical Methods · doi:10.1039/d6ay01028h · Cited by 1
Pathology of Gynecologic Cancer
DeLair, D. F. (2012) · Springer eBooks · doi:10.1007/978-1-4471-4605-6_2 · Cited by 1
“Unlike its serous counterpart, they typically do not show mutations in Tp53 [ 100, 104 ] .”
Cadherin-Catenin Signaling in Ovarian Cancer Progression
Cheung, L. W. T., Ip, C. K. M., & Wong, A. S. T. (2010) · Cancer metastasis · doi:10.1007/978-90-481-9522-0_12 · Cited by 1
Targeted Drug Delivery in Oncology: Current Paradigm and Challenges
Stirland, D. L., & Bae, Y. H. (2013) · Royal Society of Chemistry eBooks · doi:10.1039/9781849737388-00001 · Cited by 1
McNeish, I. A. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw254 · Cited by 1
Immunohistochemistry of Gynecologic Malignancies
Wang, Y., & Mhawech-Fauceglia, P. Y. (2017) · Springer eBooks · doi:10.1007/978-3-319-17798-4_65 · Cited by 1
Rubina, H., Ratnagiri, R., Uppin, M. S., Ayesha, S. M., Meher Lakshmi, K., Bala, S. C., & Uppin, S. G. (2023) · Indian Journal of Surgical Oncology · doi:10.1007/s13193-023-01756-2 · Cited by 1
“Immunohistochemistry was not found to be very reliable in mucinous carcinomas of ovary where morphology is reproducible [28, 29].”
BackgroundSurface Epithelial Tumors: Pathology Introduction
Gilks, C. B. (2011) · Springer eBooks · doi:10.1007/978-1-4419-9751-7_4 · Cited by 1
“, the more aggressive serous carcinomas) and do not have prognostic significance that is independent of tumor cell type [10].”
BackgroundSelf-citationПРОГНОСТИЧЕСКОЕ ЗНАЧЕНИЕ ЭКСПРЕССИИ р53 И с-erbB-2 ОНКОПРОТЕИНОВ ПРИ РАКЕ ЯИЧНИКОВ
Shulga, A. V., Басинский, В. А., & Савицкий, С. Э. (2009) · Electronic archive of the library (Vitebsk State Medical University) · Cited by 1
Ovarian cancer: symptoms, treatment and long-term patient management
Lanceley, A., Fitzgerald, D., Jones, V., Miles, T., Elliott, E., Darragh, L., & Peck, L. (2011) · Cancer Nursing Practice · doi:10.7748/cnp2011.05.10.4.29.c8503 · Cited by 1
Janczar, S. (2010) · Spiral (Imperial College London) · doi:10.25560/5859 · Cited by 1
♂♀Ovarian Epithelial–Stromal Tumors and Similar Lesions in the Testis
Raspollini, M. R., Montagnani, I., Montironi, R., & López-Beltrán, A. (2019) · Cambridge University Press eBooks · doi:10.1017/9781316756423.007 · Cited by 1
Cell Cycle Regulator p27 Mediates Body Mass Index Effects in Ovarian Cancer in FIGO-stages I-II
Skírnisdóttir, I., Åkerud, H., Seidal, T., & Poromaa, I. S. (2019) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20148 · Cited by 1
Basak, B., Mondal, S. K., Debnath, S., & Chattopadhyay, P. (2020) · International Journal of Clinical and Diagnostic Pathology · doi:10.33545/pathol.2020.v3.i3c.273 · Cited by 1
“[12] found more than 75% positivity of serous carcinoma for WT1 in contrast to less than 10% endometrioid carcinoma.”
BackgroundLinking oxidative stress and ovarian cancers
Amano, T., & Chano, T. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819547-5.00008-0 · Cited by 1
The Hallmarks of Ovarian Cancer: Actionable Genetics, Targetable Pathways, and Predictive Biomarkers
Bairi, K. E., Jarroudi, O. A., & Afqir, S. (2021) · Springer eBooks · doi:10.1007/978-981-16-1873-4_3 · Cited by 1
Par-4 in Chemoresistant Ovarian and Endometrial Cancers
Fabi, F., Adam, P., & Asselin, É. (2021) · Springer eBooks · doi:10.1007/978-3-030-80558-6_3 · Cited by 1
Singh, N., Tinker, A. V., & Gilks, C. B. (2022) · AJSP Review and Reports · doi:10.1097/pcr.0000000000000524 · Cited by 1
“Tubo-ovarian HGSC shows expression of WT1 in 90% to 96% of cases, usually diffusely and strongly, and amongOCs, this is considered amarker specific for serous differentiation.(43) This marker is therefore considered to be of some value in distinguishing ESC from tubo-ovarian HGSC, particularly if the pattern of expres…”
BackgroundSelf-citationOvarian clear cell carcinoma: research progress in oncogenesis and novel therapeutic strategies
Duan, F., Mingming, S., Chen, X., & Jiang, W. (2024) · Academia oncology. · doi:10.20935/acadonco7317 · Cited by 1
A Systematic Review on Ovarian Cancer
Shehzad, F., Naseem, S., & Irum, A. (2023) · University of Wah Journal of Computer Science · doi:10.56220/uwjcs.v4i1.60 · Cited by 1
Nunna, S. (2014) · OPUS Publication Server of the University of Stuttgart (University of Stuttgart) · doi:10.18419/opus-1452 · Cited by 1
Early Diagnosis of Epithelial Ovarian Cancer - Analysis of Novel Biomarkers
Kristjánsdóttir, B. (2013) · Gothenburg University Publications Electronic Archive (Gothenburg University) · Cited by 1
The role of the epithelial-mesenchymal transition in aggressive tumour phenotypes
Haslehurst, A. (2014) · QSpace (Queen's University Library) · Cited by 1
Role of CIP2A in carcinogenesis
Böckelman, C. (2012) · Helda - University of Helsinki Institutional Repository · Cited by 1
Targeting the Growth of Ovarian Cancer Cells
Miettinen, S. (2009) · Tampere University Institutional Repository (Tampere University) · Cited by 1
The role of immunogenic cell death in oncolytic herpes simplex virus-1 infection of cancer cells
Binks, A. W. D. (2018) · Enlighten: Theses (The University of Glasgow) · Cited by 1
Characterization of novel epigenetic targets in ovarian cancer
Wang, Z. (2014) · Corpus Université Laval (Université Laval) · Cited by 1
Perennec, T., Bourgade, R., Henno, S., Sagan, C., Toquet, C. S., Rioux-Leclercq, N. C., Kammerer‐Jacquet, S., Loussouarn, D., & Griebel, M. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.02.07.478680 · Cited by 2
Milne, K., Köbel, M., Kalloger, S. E., Barnes, R. O., Gao, D., Gilks, C. B., Watson, P. H., & Nelson, B. H. (2013) · PLoS ONE · doi:10.1371/annotation/976c923b-d991-4a33-b060-cdd8770bdf5d · Cited by 1
“We chose to first focus on high-grade serous cases, as the other histological subtypes exhibit distinct biological and clinical properties that are potentially confounding [54,55].”
BackgroundSelf-citationRambau, P., Vierkant, R. A., Intermaggio, M. P., Kelemen, L. E., Goodman, M. T., Herpel, E., Pharoah, P. D. P., Kommoss, S., Jimenez‐Liñan, M., Karlan, B. Y., et al. (2018) · The Journal of Pathology Clinical Research · doi:10.1002/cjp2.2018.4.issue-4 · Cited by 1
Self-citationCasey, L., & Khan, M. Y. A. (2022) · Encyclopedia of pathology · doi:10.1007/978-3-319-28845-1_5653-1 · Cited by 1
Rubio, C. (2023) · Academica-e (Universidad Pública de Navarra) · doi:10.48035/tesis/2454/44910 · Cited by 1
Serous Tumors, Pathology of the Ovary
Casey, L., & Khan, M. Y. A. (2023) · Encyclopedia of pathology · doi:10.1007/978-3-030-97378-0_5653 · Cited by 1
Unraveling the genetics of cancer using whole-exome sequencing
Zhang, J. (2016) · doi:10.82308/9344 · Cited by 1
Nasreddine, S. (2011) · theses.fr (ABES) · doi:10.70675/3a9264ffz1019z44bez9779z6fa8c870030e · Cited by 1
“This aspect has recently been addressed with the identification of several biomarkers for the identification of histologic subtypes and the more accurate prediction of patient outcome [4-9].”
BackgroundInvestigating the role of the extracellular matrix protein, Spondin 1, in ovarian folliculogenesis
O'Flynn, C. (2015) · Scholarship@Western (Western University) · Cited by 1
Haslene‐Hox, H. (2013) · NORA - Norwegian Open Research Archives
Implication of Clear Cell and Mucinous Histology
Naniwa, J., Itamochi, H., & Kigaw, J. (2013) · InTech eBooks · doi:10.5772/54931
“Clear cell carcinoma (CCC) has unique clinical and biological features [4].”
BackgroundEndometriosis‐Associated Ovarian Cancer
Garrett, L. A., & Carmen, M. G. D. (2014) · Wiley eBooks · doi:10.1002/9781118655344.ch8
Darb‐Esfahani, S. (2013) · Universitätsbibliothek der FU Berlin Hochschulschriftenstelle u. Dokumentenserver · doi:10.17169/refubium-8278
Matriptase-2 and the biological behaviours of prostate cancer cells: a possible role for β-catenin
Webb, S. L. (2011) · UPT. Syiah Kuala University Library (Syiah Kuala University)
The Role of Trop2 Cleavage Products in Prostate Tumorigenesis
Stoyanova, T. I. (2013) · Defense Technical Information Center (DTIC) · doi:10.21236/ada588256
“…advanced squamous cell carcinoma of the oral cavity and colorectal, pancreatic, gastric, and ovarian cancer, and its high levels correlate with poor prognosis and survival (Nakashima et al. 2004; Ohmachi et al. 2006; Fong et al. 2008a,b; Kobel et al. 2008; Fang et al. 2009; Muhlmann et al. 2009).”
BackgroundFreydanck, M. K. (2013) · Elektronische Hochschulschriften der LMU München (Ludwig-Maximilians-Universität München) · doi:10.5282/edoc.16196
Investigating the role of the extracellular matrix protein, Spondin 1, in ovarian folliculogenesis
O'Flynn, C. (2015) · Scholarship@Western (Western University)
Defining the roles of autophagy in ovarian carcinoma
Spowart, J. E. (2012) · UVic’s Research and Learning Repository (University of Victoria)
Investigating the Therapeutic Efficacy of a Novel Inhibitor GAP-107B8 on Ovarian Cancer Cells
Yan, F. (2011) · uO Research (University of Ottawa) · doi:10.20381/ruor-6054
“The serous, mucinous, endometrioid and clear cell tumours resembles fallopian tube, cervical, endometrium and vaginal epithelium, respectively (Auersperg et al., 2001; Bast et al., 2009; Bell, 2005; Bowtell, 2010; Kobel et al., 2008).”
Modulation of the ovarian cancer humoral response by tumor-derived exosomes.
Roberson, C. D. (2014) · ThinkIR: The University of Louisville's Institutional Repository (University of Louisville) · doi:10.18297/etd/1771
“The complexity of ovarian cancer is enhanced by its heterogeneity [28] demonstrated through the presentation of numerous histological subtypes [29] .”
BackgroundMeta-analysis of the prognostic role of p53: Playground for solution or source of confusion?
Levidou, G., Fragkou, P., Patsouris, E., & Korkolopoulou, P. A. (2011) · Journal of Public Health and Epidemiology · doi:10.5897/jphe.9000070
Maretty, L., Sibbesen, J. A., & Krogh, A. (2014)
BIOLOGICAL MECHANISMS IN OVARIAN CARCINOGENESIS INITIATION AND PROGRESSION
Lozneanu, L. (2013)
Crumley, S. M., Okoye, E. I., Deavers, M. T., & Coffey, D. (2015) · Acta Cytologica · doi:10.1159/000443517
Intrinsic subtypes and prognostic implications in epithelial ovarian cancer
Jönsson, J.-M. (2015) · Lund University Publications (Lund University)
KISS1 and Its G Protein-Coupled Receptor (GPR54) in Cancer Progression and Metastasis
Cho, S. G. (2012) · OakTrust (Texas A&M University Libraries)
Understanding CD8 T cell function under the tumour environment condition hypoxia
Townsend, K. N. (2012) · UVic’s Research and Learning Repository (University of Victoria)
Spees, C. (2011) · OhioLink ETD Center (Ohio Library and Information Network)
Novel Functions of ErbB4 and NRG-1 in Development and Cancer
Paatero, I. (2013) · UTUPub (University of Turku)
Dong, H. P. (2013) · NVA (Nasjonalt vitenarkiv)
Earp, M. A. (2013) · cIRcle (University of British Columbia) · doi:10.14288/1.0073471
Wehder, L. (2014) · Common Library Network (Der Gemeinsame Bibliotheksverbund)
Role of receptor tyrosine kinase regulator Sprouty in ovarian cancer cells
So, W. K. (2012) · cIRcle (University of British Columbia) · doi:10.14288/1.0072775
A Case Control study of Lifestyle Factors in the Aetiology of Ovarian Cancer
Su, D. (2013) · eSpace (Curtin University)
Chesang, J. (2016) · UC Research Repository (University of Canterbury) · doi:10.26021/9956
The Future in Ovarian Cancer: Advances in Immunotherapies
Makkouk, A., Chester, C., & Kohrt, H. E. K. (2016) · Springer eBooks · doi:10.1007/978-3-319-32110-3_11
Abdallah, B. Y. (2016) · Human Biology
Cao, W., Liu, M., & Sun, B. (2013) · Clinical Oncology and Cancer Research · doi:10.3969/j.issn.1000-8179.20130790
Cheraghchi-Bashi-Astaneh, A. (2014) · doi:10.25560/39596
Findlay, J. M. (2016) · Nottingham ePrints (University of Nottingham)
Nassir, M. (2017) · Universitätsbibliothek der FU Berlin Hochschulschriftenstelle u. Dokumentenserver · doi:10.17169/refubium-15905
da Silva, F. M. G. (2017) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Adam, Á. C. (2017) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Role of Amylase in Ovarian Cancer
Mohamed, M. (2017) · Digital Commons - University of South Florida (University of South Florida)
The Role of Elevated Hyaluronan-Mediated Motility Receptor (RHAMM/HMMR) in Ovarian Cancer
Buttermore, S. T. (2017) · Digital Commons - University of South Florida (University of South Florida)
Woo, M. G. (2012) · uO Research (University of Ottawa) · doi:10.20381/ruor-5555
“It is important not to treat ovarian cancer as a single entity, but to recognize that major differences exist between subtypes and this should be reflected in research designs and ultimately in the management of the disease (Kobel et al, 2008).”
BackgroundPerfiles moleculares y patrones de recaída en cáncer de ovario
Cortijo, L. G. (2018) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Aktuelle Aspekte der Diagnostik von Ovarialtumoren
TAUBE, E. T., Braicu, E. I., Kunze, C. A., Kulbe, H., Schmitt, W., & Denkert, C. (2018) · Der Onkologe · doi:10.1007/s00761-018-0495-8
Arora, N. (2018) · cIRcle (University of British Columbia) · doi:10.14288/1.0372092
The Microbiota and Ovarian Cancer
Tanyi, J. L., & Facciabene, A. (2019) · Current cancer research · doi:10.1007/978-3-030-04155-7_11
Genomic Applications in Epithelial Ovarian Malignancies
Brenton, J. D. (2014) · Springer eBooks · doi:10.1007/978-1-4939-0727-4_28
Rambau, P. (2018) · Libraries and Cultural Resources (University of Calgary) · doi:10.11575/prism/32821
Metadata
- Authors
- Köbel, M., Kalloger, S. E., Boyd, N., McKinney, S., Mehl, E., Palmer, C., Leung, S., Bowen, N. J., Ionescu, D. N., Rajput, A., Prentice, L. M., Miller, D., Santos, J., Swenerton, K., Gilks, C. B., & Huntsman, D.
- Affiliations
- BC Cancer Agency (CA)
- Canary Foundation (US)
- Georgia Institute of Technology (US)
- Corresponding author
- Huntsman, David
- ORCID
- Venue
- PLoS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2008-12-02
- Volume
- 5
- Issue
- 12
- Pages
- e232
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- PMC
- PMC2592352
- OpenAlex
- W2129355295
- Cited by
- 814
- References
- 40
- Citations by year
- 2026: 16 · 2025: 29 · 2024: 30 · 2023: 43 · 2022: 34 · 2021: 37 · 2020: 39 · 2019: 33 · 2018: 50 · 2017: 44 · 2016: 60 · 2015: 42 · 2014: 60 · 2013: 71 · 2012: 70
- FWCI
- 59.86
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS Medicine (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- Eli Lilly and Company
- Sanofi
- Canary Foundation
- Michael Smith Health Research BC
- Eli Lilly Canada
- Canadian Institutes of Health Research (017051)
- National Cancer Institute
- Topics
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Health Sciences › Medicine › Obstetrics and Gynecology › Endometrial and Cervical Cancer Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Keywords
- ovarian carcinoma, histological subtypes, high-grade serous carcinoma, clear cell carcinoma, endometrioid carcinoma, mucinous carcinoma, tumor markers, prognostic factors, Ki-67, WT1, CA125, HE4, stage at diagnosis, survival, molecular pathogenesis, tumor cell proliferation
- MeSH terms
- Carcinoma, Diagnosis, Differential, Female, Follow-Up Studies, Humans, Middle Aged, Neoplasm Staging, Ovarian Diseases, Ovarian Neoplasms, Prognosis, Retrospective Studies, Biomarkers, Tumor, Cohort Studies, Confounding Factors, Epidemiologic, Survival Analysis, Tissue Array Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.